Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orajel joins C&D

This article was originally published in The Tan Sheet

Executive Summary

Church & Dwight adds Orajel to its brand portfolio as the firm completes its acquisition of the Del OTC pharmaceutical business from Coty Inc, according to a July 7 release. C&D paid $380 million cash at closing while the purchase price includes a $250 million addition to its bank credit facility and available cash. The Princeton, N.J.-based firm expects the acquisition, announced in April 2008, to have a "neutral impact on 2008 earnings per share due primarily to one-time integration costs and the step-up of inventory" (1"The Tan Sheet" April 7, 2008, p. 3)...

You may also be interested in...



Del OTC Acquisition Brings Orajel To Church & Dwight In $380 Million Deal

Church & Dwight agreed to acquire Del Pharmaceuticals' OTC brands, including the Orajel topical analgesic line, for $380 million in cash from Coty, Inc., the firm said April 1

Bayer Execs On Digital Acceleration, Getting The Building Blocks Right

Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”

US FDA Credibility: Surprisingly Strong, Despite Everything

A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel